Category: Second Column

Congress Protected Opiate Pushers

From Steve Robinson, MD (forwarding an October 15 Washington Post exposé): Amid a targeted lobbying effort, Congress last year weakened the DEA’s ability to go after drug distributors, even as the opioid epidemic raged and thousands of Americans were dying of overdoses, an investigation by The Washington Post and “60 Minutes” found. The “60 Minutes” report will air tonight at 7:30 Eastern and 7 Pacific. The accompanying video is heartbreaking and angering! And many of these corporate shills are the same who oppose the research on and legalization of cannabis! Retro Message:  I know you’re not surprised that Big...

Read More

Ethan Russo, MD, has a new job

A press release dateline Prague October 16, 2017: International Cannabis and Cannabinoids Institute (ICCI) welcomes Ethan Russo, MD as new Director of Research and Development. ICCI is the first-ever international Center of Excellence for the advancement of cannabis and cannabinoid treatments located in the Czech Republic. ICCI identifies, coordinates and supports global research priorities for the advancement of cannabis and cannabinoid treatments through a multidiscipline evidence-based approach that incorporates innovative tools and approaches. Ethan Russo, MD, is a board-certified pediatric and adult neurologist, psychopharmacology researcher, former Senior Medical Advisor to GW Pharmaceuticals, and Medical Director of PHYTECS. He served...

Read More

Medical Cannabis and Pain Management

Bonni Goldstein, MD, forwards this “very interesting” editorial from the January 2018 Journal of Applied Laboratory Medicine, “Medical Cannabis and Pain Management: How Might the Role of Cannabis Be Defined in Pain Medicine?” The authors, Amor Deshpande and Angela Mailis, are pain specialists based in Toronto. Very interesting, indeed. Excerpts follow with boldface showing our strong agreement. With every passing day, the din surrounding the inappropriateness of cannabinoids in pain medicine grows quieter. While it would be remarkable to attribute this acquiescence to a growing body of robust supporting evidence, the reality is that the number and quality of clinical cannabinoid trials in...

Read More

A Use for Rimonabant? (Sanofi Isn’t Interested)

Cannabinoid-receptor inverse-agonist drugs can be used as antidotes to rescue people overdosing on synthetic cannabinoids (widely marketed as “Spice,” “K2,” etc.).  So suggests a paper in the British Journal of Pharmacology by Gareth Pryce and David Baker, researchers from Queen Mary University of London. It has long been established that CB1-receptor inverse-agonist drugs, administered in advance of cannabinoid use, can block intoxication. Pryce and Baker were investigating whether the “effects of a synethic cannabinoid could be reversed after they are manifest.” Working with mice, they administered 5mg/kg of the antagonist drug AM-251 20 minutes after intoxication was induced by an...

Read More

Florida’s Rules re Medical Cannabis

The Boards of Medicine and Osteopathic Medicine released two new rules today developed by the Joint committee with respect to medical cannabis. They address a newly required uniform patient consent form as well as disciplinary guidelines for the respective Boards for improper patient certifications.  Both rules became effective immediately on October 4. Make sure you start using these new consent forms today! The Uniform Patient Consent form for MDs The Uniform Patient Consent form for DOs We are still waiting on Board rules creating a form for the “or other” conditions, which must be turned into the respective Boards...

Read More